phosphonoacetic acid has been researched along with HIV in 20 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The drug sensitivities of human immunodeficiency virus (HIV) isolates from a group of patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) who were receiving zidovudine (3'-azido-3'-deoythymidine, AZT) therapy were tested by means of a newly developed plaque assay in CD4+ HeLa cells." | 7.67 | HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. ( Darby, G; Larder, BA; Richman, DD, 1989) |
| "Foscarnet was administered by continuous intravenous infusion in 15 patients with the acquired immunodeficiency syndrome (AIDS) in an open, uncontrolled study." | 5.06 | The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients. ( Faber, V; Gaub, J; Gerstoft, J; Hofmann, B; Lernestedt, JO; Lindhardt, BO; Mathiesen, LR; Pedersen, C; Poulsen, AG; Ulrich, K, 1987) |
| "Foscarnet is a pyrophosphate analogue with activity against herpesviruses, human immunodeficiency virus (HIV), and other RNA and DNA viruses." | 4.78 | Mechanism of action of foscarnet against viral polymerases. ( Crumpacker, CS, 1992) |
| "Disodium palmityl phosphonoformate, a novel lipid phosphoester of the anti HIV agent phosphonoformate (foscarnet), inhibits HIV replication in H9 cells and syncytia formation in MOLT-3 cells as effectively as foscarnet itself, as shown by dose-response data from assays for expression of p17 and p24 viral antigens and syncytia formation." | 3.68 | Lipid conjugates of antiretroviral agents. II. Disodium palmityl phosphonoformate: anti-HIV activity, physical properties, and interaction with plasma proteins. ( Bhongle, NN; Camaioni Neto, C; Piratla, RK; Sarin, PS; Steim, JM; Sun, DK; Turcotte, JG, 1990) |
| "The drug sensitivities of human immunodeficiency virus (HIV) isolates from a group of patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) who were receiving zidovudine (3'-azido-3'-deoythymidine, AZT) therapy were tested by means of a newly developed plaque assay in CD4+ HeLa cells." | 3.67 | HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. ( Darby, G; Larder, BA; Richman, DD, 1989) |
| " It is thus difficult to formulate optimal dosing regimens on the basis of what is known of foscarnet pharmacodynamics and pharmacokinetics." | 2.38 | Clinical pharmacology: foscarnet. ( Lietman, PS, 1992) |
| " The combined effect of ddNTPs and the pyrophosphate analog phosphonoformate (PFA) on HIV reverse transcriptase was also examined, and inhibition by PFA in combination with ddTTP or AZTTP was mutually exclusive." | 1.28 | Inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxynucleoside triphosphates: template dependence, and combination with phosphonoformate. ( Cheng, YC; Starnes, MC, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (65.00) | 18.7374 |
| 1990's | 7 (35.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bailey, JM | 1 |
| Lightfoote, M | 1 |
| Lillehoj, E | 1 |
| Nelson, K | 1 |
| Crumpacker, CS | 1 |
| Lietman, PS | 1 |
| Tao, P | 1 |
| Zhang, X | 1 |
| Quan, K | 1 |
| Cox, S | 1 |
| Koshida, R | 1 |
| Harmenberg, J | 1 |
| Wahren, B | 1 |
| Camaioni Neto, C | 1 |
| Steim, JM | 1 |
| Sarin, PS | 1 |
| Sun, DK | 1 |
| Bhongle, NN | 1 |
| Piratla, RK | 1 |
| Turcotte, JG | 1 |
| Snoeck, R | 1 |
| Lagneaux, L | 1 |
| Delforge, A | 1 |
| Bron, D | 1 |
| Van der Auwera, P | 1 |
| Stryckmans, P | 1 |
| Balzarini, J | 1 |
| De Clercq, E | 1 |
| Vogt, M | 1 |
| Schooley, RT | 1 |
| Hirsch, MS | 1 |
| Frank, KB | 1 |
| McKernan, PA | 1 |
| Smith, RA | 1 |
| Smee, DF | 1 |
| Wondrak, EM | 1 |
| Löwer, J | 1 |
| Kurth, R | 1 |
| Larder, BA | 1 |
| Darby, G | 1 |
| Richman, DD | 1 |
| Montefiori, DC | 1 |
| Robinson, WE | 1 |
| Mitchell, WM | 1 |
| Starnes, MC | 1 |
| Cheng, YC | 1 |
| Crowe, SM | 1 |
| McGrath, MS | 1 |
| Elbeik, T | 1 |
| Kirihara, J | 1 |
| Mills, J | 2 |
| Yarchoan, R | 1 |
| Broder, S | 1 |
| Jacobson, MA | 1 |
| Crowe, S | 1 |
| Levy, J | 1 |
| Aweeka, F | 1 |
| Gambertoglio, J | 1 |
| McManus, N | 1 |
| Bergdahl, S | 1 |
| Sönnerborg, A | 1 |
| Larsson, A | 1 |
| Strannegard, O | 1 |
| Weber, J | 1 |
| Farthing, CF | 1 |
| Dalgleish, AG | 1 |
| Clark, A | 1 |
| McClure, M | 1 |
| Chanas, A | 1 |
| Gazzard, BG | 1 |
| Gaub, J | 1 |
| Pedersen, C | 1 |
| Poulsen, AG | 1 |
| Mathiesen, LR | 1 |
| Ulrich, K | 1 |
| Lindhardt, BO | 1 |
| Faber, V | 1 |
| Gerstoft, J | 1 |
| Hofmann, B | 1 |
| Lernestedt, JO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome[NCT00000726] | Phase 1 | 53 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for phosphonoacetic acid and HIV
| Article | Year |
|---|---|
Mechanism of action of foscarnet against viral polymerases.
Topics: Antiviral Agents; DNA-Directed RNA Polymerases; Drug Interactions; Drug Resistance, Microbial; Fosca | 1992 |
Clinical pharmacology: foscarnet.
Topics: Antiviral Agents; Foscarnet; HIV; Humans; Nucleic Acid Synthesis Inhibitors; Phosphonoacetic Acid; R | 1992 |
Progress in the development of antiviral therapy for HTLV-III-associated diseases.
Topics: Acquired Immunodeficiency Syndrome; Antimony; Antiviral Agents; Foscarnet; HIV; Humans; Phosphonoace | 1987 |
3 trials available for phosphonoacetic acid and HIV
| Article | Year |
|---|---|
[Chemotherapy and immunoprophylaxis of HIV infection].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Foscarnet; HIV; Huma | 1986 |
Phosphonoformate (foscarnet): a pilot study in AIDS and AIDS related complex.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Antigens, Viral; Clinical Trials as Topic; | 1987 |
The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antibodies, Viral; Clinical Trials as Topic; Foscarnet; H | 1987 |
14 other studies available for phosphonoacetic acid and HIV
| Article | Year |
|---|---|
Synthesis and antiviral properties of sterol phosphonoformates.
Topics: Antiviral Agents; Cholesterol Esters; Culture Techniques; Foscarnet; HIV; Humans; Phosphonoacetic Ac | 1994 |
The characterization of EIAV reverse transcriptase and its inhibition by 5'-triphosphates of 2'-deoxyuridine analogs, PFA and PAA.
Topics: Antiviral Agents; Dideoxynucleotides; Foscarnet; HIV; Infectious Anemia Virus, Equine; Phosphonoacet | 1990 |
Synergistic combinations and peptides in the inhibition of human immunodeficiency virus.
Topics: Alpha-Globulins; Amino Acid Sequence; Antiviral Agents; Cell Line; Dideoxynucleosides; Drug Synergis | 1991 |
Lipid conjugates of antiretroviral agents. II. Disodium palmityl phosphonoformate: anti-HIV activity, physical properties, and interaction with plasma proteins.
Topics: Antiviral Agents; Cell Fusion; Cell Line; Chemical Phenomena; Chemistry, Physical; Foscarnet; HIV; I | 1990 |
Inhibitory effects of potent inhibitors of human immunodeficiency virus and cytomegalovirus on the growth of human granulocyte-macrophage progenitor cells in vitro.
Topics: Adenine; Adult; Antiviral Agents; Bone Marrow; Bone Marrow Cells; Cells, Cultured; Cidofovir; Cytome | 1990 |
Visna virus as an in vitro model for human immunodeficiency virus and inhibition by ribavirin, phosphonoformate, and 2',3'-dideoxynucleosides.
Topics: Antimetabolites; Antiviral Agents; Deoxyribonucleosides; Deoxyribonucleotides; Foscarnet; HIV; Organ | 1987 |
Inhibition of HIV-1 RNA-dependent DNA polymerase and cellular DNA polymerases alpha, beta and gamma by phosphonoformic acid and other drugs.
Topics: Antiviral Agents; DNA Polymerase I; DNA Polymerase II; DNA Polymerase III; Foscarnet; HIV; In Vitro | 1988 |
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Dideoxynucleosides; Drug Resistance; Fosca | 1989 |
In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Alkaloids; Amphotericin B; Antiviral Agents; Drug Therapy, Combi | 1989 |
Inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxynucleoside triphosphates: template dependence, and combination with phosphonoformate.
Topics: Acquired Immunodeficiency Syndrome; Dideoxynucleosides; Dinucleoside Phosphates; DNA Replication; DN | 1989 |
Comparative assessment of antiretrovirals in human monocyte-macrophages and lymphoid cell lines acutely and chronically infected with the human immunodeficiency virus.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Foscarnet; Gene Products, gag; HIV; HIV Antigens | 1989 |
Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; HIV; HI | 1988 |
Declining levels of HIV P24 antigen in serum during treatment with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Antigens, Viral; Antiviral Agents; Foscarnet; HIV; HIV Antigens; | 1988 |
AIDS: the virus, antivirals and vaccines.
Topics: Acquired Immunodeficiency Syndrome; Antimony; Antiviral Agents; Foscarnet; Genes, Viral; HIV; Humans | 1987 |